CN115925700B — 一种酪氨酸激酶抑制剂的晶型及其制备方法
Assigned to Luoxin Biotechnology Shanghai Co ltd · Expires 2025-02-18 · 1y expired
What this patent protects
本发明公开了一种酪氨酸激酶抑制剂培西达替尼盐酸盐的晶型LX‑I及其制备方法。本发明的培西达替尼盐酸盐晶型LX‑I，其以2θ角度表示的X‑射线粉末衍射图在6.6±0.2°、12.2±0.2°、16.0±0.2°、18.4±0.2°、19.8±0.2°和20.8±0.2°处有衍射峰，差示扫描量热图在234.6±5℃处具有吸热峰。该晶型有较好的稳定性、溶解性和流动性并且其制备工艺简单可控，具有较好的成药前景。
USPTO Abstract
本发明公开了一种酪氨酸激酶抑制剂培西达替尼盐酸盐的晶型LX‑I及其制备方法。本发明的培西达替尼盐酸盐晶型LX‑I，其以2θ角度表示的X‑射线粉末衍射图在6.6±0.2°、12.2±0.2°、16.0±0.2°、18.4±0.2°、19.8±0.2°和20.8±0.2°处有衍射峰，差示扫描量热图在234.6±5℃处具有吸热峰。该晶型有较好的稳定性、溶解性和流动性并且其制备工艺简单可控，具有较好的成药前景。
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.